New England Journal / Creative Commons / U. Fedeli S. A. / Hindawi Publishing Corporation / /
Continent
Europe / /
Country
United States / / /
Event
Product Issues / Product Recall / Business Partnership / /
Facility
Science University / National Cancer Institute / University of Washington / University of Wisconsin / /
IndustryTerm
therapy for muscle invasive bladder cancer / treatment of more aggressive disease / treatment of muscle invasive bladder cancer / cancer treatment / care of oncologic diseases / online survey tool / treatment of muscle-invasive bladder cancer / /
MedicalCondition
greater disease / urothelial carcinoma / Bladder Cancer / III bladder cancer / chronic kidney disease / I never superficial disease / high-volume T2 disease / high-volume clinical T2 disease / muscle invasive bladder cancer / stage T2 disease / oncologic diseases / invasive bladder cancer / adjuvant setting renal insufficiency / GU multidisciplinary tumor / cancer / disease / hydronephrosis / muscle-invasive bladder cancer / Conclusions Clinical T3-T4 disease / T2 disease / cT2-T 4aN0M0 bladder cancer / initial bladder cancer / muscle-invasive and metastatic bladder cancer / decreased disease / aggressive disease / clinical T2 disease / locally advanced bladder cancer / clinical T3-T4 disease / baseline renal insufficiency / reported tumor / Clinical T3/T4 disease / muscleinvasive bladder cancer / localized bladder cancer / /
National Cancer Institute / Preventive Medicine / Oregon Health and Science University / Urology Service / Department of Urology / Society for Urologic Oncology / USA Department of Public Health and Preventive Medicine / European Association of Urology / University of Washington / Seattle / University of Wisconsin / Madison / Department of Surgery / Urology / Oregon Health and Science University / /
Person
J. M. Hassan / A. Dash / M. S. Cookson / S. S. Chang / J. A. Smith Jr. / N. Wells / Douglas S. Scherr / /
Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions